Company: CSTL
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001447362-25-000097
Chunk: 49

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-08-04
Form: 10-Q
Item: Item 1
Chunk 49
---
(unaudited)Net revenues$174,176 $159,976 $14,200 8.9 %Operating expensesCost of sales (exclusive of amortization of acquired intangible assets)34,009 28,413 5,596 19.7 %Research and development25,375 27,945 (2,570)(9.2)%Selling, general and administrative116,685 99,583 17,102 17.2 %Amortization of acquired intangible assets30,286 4,494 25,792 573.9 %Total operating expenses, net206,355 160,435 45,920 28.6 %Operating loss(32,179)(459)(31,720)NMInterest income6,043 6,140 (97)(1.6)%Changes in fair value of trading securities(240)— (240)NAInterest expense(38)(284)246 86.6 %(Loss) income before income taxes(26,414)5,397 (31,811)(589.4)%Income tax benefit(5,089)(989)(4,100)(414.6)%Net (loss) income$(21,325)$6,386 $(27,711)(433.9)%

NA = Not applicable

NM = Not meaningful

The following table indicates the amount of stock-based compensation expense (non-cash) reflected in the line items above (in thousands):

Six Months EndedJune 30,20252024Change(unaudited)Cost of sales (exclusive of amortization of acquired intangible assets)$2,878 $2,715 $163 Research and development3,857 5,266 (1,409)Selling, general and administrative15,652 17,873 (2,221)Total stock-based compensation expense$22,387 $25,854 $(3,467)

37

The following table provides a disaggregation of net revenues by type (in thousands):

Six Months EndedJune 30,20252024Change(unaudited)Dermatologic(1)$119,259 $128,163 $(8,904)Non-Dermatologic(2)54,917 31,813 23,104 Total net revenues$174,176 $159,976 $14,200 

(1)Consists of DecisionDx-Melanoma